MUHC Publications: November 2021 – November 2022

MUHC Activities

1. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, Tikhonov I, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Arasaradnam RP, Afif W, Peyrin-Biroulet L, Sands BE, Marano C.J Crohns Colitis. 2022 Aug 30;16(8):1222-1234. doi: 10.1093/ecco-jcc/jjac030.PMID: 35239968
2. Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial. Afif W, Sattin B, Dajnowiec D, Khanna R, Seow CH, Williamson M, Karra K, Wang Y, Gao LL, Bressler B.Dig Dis Sci. 2022 Jul;67(7):3148-3157. doi: 10.1007/s10620-021-07173-1. Epub 2021 Aug 17.PMID: 34401983
3. Depression, diabetes and immigration status: a retrospective cohort study using the Canadian Longitudinal Study on Aging. Farid D, Li P, Da Costa D, Afif W, Szabo J, Dasgupta K, Rahme E.CMAJ Open. 2022 Jun 14;10(2):E508-E518. doi: 10.9778/cmajo.20210019. Print 2022 Apr-Jun.PMID: 35700994
4. Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn’s and Colitis Canada. Fu N, Bollegala N, Jacobson K, Kroeker KI, Frost K, Afif W, El-Matary W, Fowler SA, Griffiths AM, Huynh HQ, Jantchou P, Karimuddin A, Nguyen GC, Otley AR, Pears C, Seow CH, Toulany A, Tersigni C, Tignanelli J, Marshall JK, Boctor M, Hansen T, Pattni C, Wong A, Benchimol EI.J Can Assoc Gastroenterol. 2022 Mar 26;5(3):105-115. doi: 10.1093/jcag/gwab050. eCollection 2022 Jun.PMID: 35669843
5. The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project). de-Madaria E, Mira JJ, Carrillo I, Afif W, Ang D, Antelo M, Bollipo S, Castells A, Chahal P, Heinrich H, Law JK, van Leerdam ME, Lens S, Pannala R, Park SH, Rabiee A, Savarino EV, Singh VK, Vargo J, Charabaty A, Drenth JPH.Lancet Gastroenterol Hepatol. 2022 May;7(5):485-494. doi: 10.1016/S2468-1253(21)00442-8. Epub 2022 Mar 2.PMID: 35247318
6. Epidermolysis bullosa acquisita treated with ustekinumab: A case report. Prosty C, Guirguis J, Chergui M, Afif W, Netchiporouk E.SAGE Open Med Case Rep. 2022 Apr 14;10:2050313X221091600. doi: 10.1177/2050313X221091600. eCollection 2022.PMID: 35449527
7. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. Danese S, Sands BE, Abreu MT, O’Brien CD, Bravatà I, Nazar M, Miao Y, Wang Y, Rowbotham D, Leong RWL, Arasaradnam RP, Afif W, Marano C.Clin Gastroenterol Hepatol. 2022 Mar 8:S1542-3565(22)00207-5. doi: 10.1016/j.cgh.2022.02.050. Online ahead of print.PMID: 35276329
8. Medical Summary Template for the Transfer of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care. Benchimol EI, Afif W, Plamondon S, Newhook D, Nicholls SG, Lévesque D.J Can Assoc Gastroenterol. 2021 May 15;5(1):3-11. doi: 10.1093/jcag/gwab009. eCollection 2022 Feb.PMID: 35118221
9. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring.Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5.PMID: 35026171
10. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study. Bessissow T, Nguyen GC, Tarabain O, Peyrin-Biroulet L, Foucault N, McHugh K, Ruel J.World J Gastroenterol. 2022 Sep 14;28(34):5058-5075. doi: 10.3748/wjg.v28.i34.5058.PMID: 36160646
11. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn’s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Shehab M, Alrashed F, Heron V, Restellini S, Bessissow T.Inflamm Bowel Dis. 2022 May 23:izac103. doi: 10.1093/ibd/izac103. Online ahead of print.PMID: 35604382
12. Fecal Diversion for Perianal Crohn Disease in the Era of Biologic Therapies: A Multicenter Study. McCurdy JD, Reid J, Yanofsky R, Sinnathamby V, Medawar E, Williams L, Bessissow T, Rosenfeld G.Inflamm Bowel Dis. 2022 Feb 1;28(2):226-233. doi: 10.1093/ibd/izab086.PMID: 33988225
13. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility. Sazonovs A, Stevens CR, Venkataraman GR, Yuan K, Avila B, Abreu MT, Ahmad T, Allez M, Ananthakrishnan AN, Atzmon G, Baras A, Barrett JC, Barzilai N, Beaugerie L, Beecham A, Bernstein CN, Bitton A, Bokemeyer B, Chan A, Chung D, Cleynen I, Cosnes J, Cutler DJ, Daly A, Damas OM, Datta LW, Dawany N, Devoto M, Dodge S, Ellinghaus E, Fachal L, Farkkila M, Faubion W, Ferreira M, Franchimont D, Gabriel SB, Ge T, Georges M, Gettler K, Giri M, Glaser B, Goerg S, Goyette P, Graham D, Hämäläinen E, Haritunians T, Heap GA, Hiltunen M, Hoeppner M, Horowitz JE, Irving P, Iyer V, Jalas C, Kelsen J, Khalili H, Kirschner BS, Kontula K, Koskela JT, Kugathasan S, Kupcinskas J, Lamb CA, Laudes M, Lévesque C, Levine AP, Lewis JD, Liefferinckx C, Loescher BS, Louis E, Mansfield J, May S, McCauley JL, Mengesha E, Mni M, Moayyedi P, Moran CJ, Newberry RD, O’Charoen S, Okou DT, Oldenburg B, Ostrer H, Palotie A, Paquette J, Pekow J, Peter I, Pierik MJ, Ponsioen CY, Pontikos N, Prescott N, Pulver AE, Rahmouni S, Rice DL, Saavalainen P, Sands B, Sartor RB, Schiff ER, Schreiber S, Schumm LP, Segal AW, Seksik P, Shawky R, Sheikh SZ, Silverberg MS, Simmons A, Skeiceviciene J, Sokol H, Solomonson M, Somineni H, Sun D, Targan S, Turner D, Uhlig HH, van der Meulen AE, Vermeire S, Verstockt S, Voskuil MD, Winter HS, Young J; Belgium IBD Consortium; Cedars-Sinai IBD; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; NIHR IBD BioResource; Regeneron Genetics Center; SHARE Consortium; SPARC IBD Network; UK IBD Genetics Consortium, Duerr RH, Franke A, Brant SR, Cho J, Weersma RK, Parkes M, Xavier RJ, Rivas MA, Rioux JD, McGovern DPB, Huang H, Anderson CA, Daly MJ.Nat Genet. 2022 Sep;54(9):1275-1283. doi: 10.1038/s41588-022-01156-2. Epub 2022 Aug 29.PMID: 36038634
14. Prostaglandins and calprotectin are genetically and functionally linked to the Inflammatory Bowel Diseases. Karaky M, Boucher G, Mola S, Foisy S, Beauchamp C, Rivard ME, Burnette M, Gosselin H; iGenoMed Consortium, Bitton A, Charron G, Goyette P, Rioux JD.PLoS Genet. 2022 Sep 26;18(9):e1010189. doi: 10.1371/journal.pgen.1010189. eCollection 2022 Sep.PMID: 36155972 Free PMC article. 
15. Hospitalization With Clostridioides difficile in Pediatric Inflammatory Bowel Disease: a Population-Based Study. Kuenzig ME, Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Griffiths AM, Kaplan GG, Nguyen GC, Otley AR, Stukel TA, Dummer TJB, El-Matary W, Jacobson K, Jones JL, Lix LM, Mack DR, Murthy SK, Peña-Sánchez JN, Targownik LE, Fung SG, Spruin S, Coward S, Cui Y, Filliter C, Nugent Z, Siddiq S, Singh H; Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC).J Pediatr Gastroenterol Nutr. 2022 Aug 1;75(2):173-180. doi: 10.1097/MPG.0000000000003489. Epub 2022 Jun 7.PMID: 35675701
16. IBD-associated G protein-coupled receptor 65 variant compromises signalling and impairs key functions involved in inflammation. Mercier V, Boucher G, Devost D, Bourque K, Alikashani A, Beauchamp C, Bitton A, Foisy S, Goyette P, Charron G, Hébert TE, Rioux JD.Cell Signal. 2022 May;93:110294. doi: 10.1016/j.cellsig.2022.110294. Epub 2022 Feb 24.PMID: 35218908
17. Serum Analyte Profiles Associated With Crohn’s Disease and Disease Location. Boucher G, Paradis A, Chabot-Roy G, Coderre L, Hillhouse EE, Bitton A, Des Rosiers C, Levings MK, Schumm LP, Lazarev M, Brant SR, Duerr R, McGovern D, Silverberg MS, Cho J, Lesage S, Rioux JD; iGenoMed Consortium; NIDDK IBD Genetics Consortium.Inflamm Bowel Dis. 2022 Jan 5;28(1):9-20. doi: 10.1093/ibd/izab123.PMID: 34106269
18. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response. Heron V, Li Fraine S, Panaccione N, Restellini S, Germain P, Candido K, Bernstein CN, Bessissow T, Bitton A, Chauhan UK, Lakatos PL, Marshall JK, Michetti P, Seow CH, Rosenfeld G, Panaccione R, Afif W.J Can Assoc Gastroenterol. 2022 May 26;5(5):208-213. doi: 10.1093/jcag/gwac017. eCollection 2022 Oct.PMID: 36196277 Free PMC article. 
19. Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis. Bessissow T, Kron CM, Marcus V, Lemieux C, Laneuville J, Afif W, Wild G,Lakatos PL, Brassard P, Bitton A.Am J Gastroenterol. 2022 Oct 1;117(10):1632-1638. doi: 10.14309/ajg.0000000000001912. Epub 2022 Jul 21.PMID: 35862833
20. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. CORE-IBD Collaborators, Ma C, Hanzel J, Panaccione R, Sandborn WJ, D’Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V. 2022 Oct;163(4):950-964. doi: 10.1053/j.gastro.2022.06.068. Epub 2022 Jul 3.PMID: 35788348
21. Epidemiology, treatment strategy, natural disease course and surgical outcomes of patients with ulcerative colitis in Western Hungary – a population-based study between 2007 and 2018, data from the Veszprem County cohort. Kurti Z, Gonczi L, Lakatos L, Golovics P, Pandur T, David G, Erdelyi Z, Szita I, Lakatos PL.J Crohns Colitis. 2022 Sep 19:jjac142. doi: 10.1093/ecco-jcc/jjac142. Online ahead of print.PMID: 36125105
22. Incidence, prevalence, disease course and treatment strategy of Crohn’s disease patients from the Veszprem cohort, Western Hungary – a population-based inception cohort study between 2007 and 2018. Gonczi L, Lakatos L, Kurti Z, Golovics P, Pandur T, David G, Erdelyi Z, Szita I, Lakatos PL.J Crohns Colitis. 2022 Sep 10:jjac132. doi: 10.1093/ecco-jcc/jjac132. Online ahead of print.PMID: 36087109
23. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study. Hahn GD, LeBlanc JF, Golovics PA, Wetwittayakhlang P, Qatomah A, Wang A, Boodaghians L, Liu Chen Kiow J, Al Ali M, Wild G, Afif W, Bitton A, Lakatos PL, Bessissow T.World J Gastroenterol. 2022 Sep 7;28(33):4823-4833. doi: 10.3748/wjg.v28.i33.4823.PMID: 36156919 Free PMC article. 
24. The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD). Azhari H, King JA, Coward S, Windsor JW, Ma C, Shah SC, Ng SC, Mak JWY, Kotze PG, Ben-Horin S, Loftus EV Jr, Lees CW, Gearry R, Burisch J, Lakatos PL, Calvet X, Bosques Padilla FJ, Underwood FE, Kaplan GG.Am J Gastroenterol. 2022 Sep 1;117(9):1419-1427. doi: 10.14309/ajg.0000000000001843. Epub 2022 Jun 2.PMID: 35973143
25. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study. Lontai L, Gonczi L, Balogh F, Komlodi N, Resal T, Farkas K, Molnar T, Miheller P, Golovics PA, Schafer E, Szamosi T, Ilias A, Lakatos PL.Dig Liver Dis. 2022 Aug 2:S1590-8658(22)00592-8. doi: 10.1016/j.dld.2022.07.004. Online ahead of print.PMID: 35931624
26. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers. Rivière P, Kanters C, Pellet G, Ni A, Hupé M, Aboulhamid N, Poullenot F, Bitton A, Zerbib F, Lakatos PL, Afif W, Laharie D, Bessissow T.Inflamm Bowel Dis. 2022 Aug 2:izac167. doi: 10.1093/ibd/izac167. Online ahead of print.PMID: 35917111
27. Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. Lakatos PL, Kaplan GG, Bressler B, Khanna R, Targownik L, Jones J, Rahal Y, McHugh K, Panaccione R.J Can Assoc Gastroenterol. 2022 Mar 10;5(4):169-176. doi: 10.1093/jcag/gwac001. eCollection 2022 Aug.PMID: 35919766 Free PMC article.

30. Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Hahn GD, Golovics PA, Wetwittayakhlang P, Santa Maria DM, Britto U, Wild GE, Afif W, Bitton A, Bessissow T, Lakatos PL.J Clin Med. 2022 Jul 29;11(15):4422. doi: 10.3390/jcm11154422.PMID: 35956040 Free PMC article. 
31. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. Golovics PA, Gonczi L, Reinglas J, Verdon C, Pundir S, Afif W, Wild G, Bitton A, Bessissow T,Lakatos PL.Dig Dis Sci. 2022 Jul;67(7):3089-3095. doi: 10.1007/s10620-021-07178-w. Epub 2021 Jul 20.PMID: 34286411
32. Serological biomarkers for management of primary sclerosing cholangitis. Tornai D, Ven PL, Lakatos PL, Papp M.World J Gastroenterol. 2022 Jun 7;28(21):2291-2301. doi: 10.3748/wjg.v28.i21.2291.PMID: 35800183 Free PMC article. 
33. Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review. Al Khoury A, Balram B, Bessissow T, Afif W, Gonczi L, Abreu M, Lakatos PL.Dig Dis Sci. 2022 Jun;67(6):1956-1974. doi: 10.1007/s10620-021-07025-y. Epub 2021 May 21.PMID: 34021425 Free PMC article. 
34. The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials. Wetwittayakhlang P, Al Khoury A, Hahn GD, Lakatos PL.J Clin Med. 2022 May 28;11(11):3045. doi: 10.3390/jcm11113045.PMID: 35683433 Free PMC article. 
35. Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease. Quan J, Ma C, Panaccione R, Hracs L, Sharifi N, Herauf M, Makovinović A, Coward S, Windsor JW, Caplan L, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group (Lakatos PL) . 2022 May 23:gutjnl-2022-327440. doi: 10.1136/gutjnl-2022-327440. Online ahead of print.PMID: 35606090 No abstract available.
36. A systematic review and functional bioinformatics analysis of genes associated with Crohn’s disease identify more than 120 related genes. Garza-Hernandez D, Sepulveda-Villegas M, Garcia-Pelaez J, Aguirre-Gamboa R, Lakatos PL, Estrada K, Martinez-Vazquez M, Trevino V.BMC Genomics. 2022 Apr 13;23(1):302. doi: 10.1186/s12864-022-08491-y.PMID: 35418025 Free PMC article. 
37. Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing? Hahn GD, Golovics PA, Wetwittayakhlang P, Al Khoury A, Bessissow T, Lakatos PL. 2022 Mar 23;10(4):749. doi: 10.3390/biomedicines10040749.PMID: 35453498 Free PMC article.Review.
38. Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn’s Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance. Hahn GD, Wetwittayakhlang P, Afif W, Bessissow T, Lakatos PL.Case Rep Gastroenterol. 2022 Mar 17;16(1):116-121. doi: 10.1159/000521919. eCollection 2022 Jan-Apr.PMID: 35528765 Free PMC article. 
39. Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Xiao Y, Benoit N, Sedano R, Jairath V, Narula N, McCurdy JD, Rosenfeld G, Afif W, Lakatos PL, Bessissow T.Dig Dis Sci. 2022 Mar 4. doi: 10.1007/s10620-022-07439-2. Online ahead of print.PMID: 35244825

42. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O’Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L.Lancet Gastroenterol Hepatol. 2022 Mar;7(3):254-261. doi: 10.1016/S2468-1253(21)00297-1. Epub 2022 Jan 17.PMID: 35051383
43. Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn’s Disease. Battat R, Qatomah A, Kopylov U, Wyse J, Cohen A, Afif W, Lakatos PL, Seidman E, Bitton A, Bessissow T.J Clin Gastroenterol. 2022 Mar 1;56(3):e166-e170. doi: 10.1097/MCG.0000000000001626.PMID: 34739405
44. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Doherty G, Raine T, Panis Y.J Crohns Colitis. 2022 Feb 23;16(2):179-189. doi: 10.1093/ecco-jcc/jjab177.PMID: 34635910
45. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O’Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L.Clin Gastroenterol Hepatol. 2022 Feb 19:S1542-3565(22)00188-4. doi: 10.1016/j.cgh.2022.02.032. Online ahead of print.PMID: 35189386
46. Clinical efficacy, drug sustainability and serum drug levels in Crohn’s disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary. Gonczi L, Szanto K, Farkas K, Molnar T, Szamosi T, Schafer E, Golovics PA, Barkai L, Lontai L, Lovasz B, Juhasz M, Patai A, Sarang K, Vincze A, Sarlos P, Farkas A, Dubravcsik Z, Toth TG, Miheller P, Ilias A, Lakatos PL.Dig Liver Dis. 2022 Feb;54(2):207-213. doi: 10.1016/j.dld.2021.07.008. Epub 2021 Jul 31.PMID: 34344576
47. Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease. Santella C, Bitton A, Filliter C, Bessissow T, Vutcovici M, Lakatos PL, Brassard P.Inflamm Bowel Dis. 2022 Feb 1;28(2):176-182. doi: 10.1093/ibd/izab092.PMID: 33999136
48. Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996-2015. Golovics PA, Verdon C, Wetwittayakhlang P, Filliter C, Gonczi L, Hahn GD, Wild GE, Afif W, Bitton A, Bessissow T, Brassard P, Lakatos PL.J Clin Med. 2022 Jan 28;11(3):686. doi: 10.3390/jcm11030686.PMID: 35160136 Free PMC article. 
49. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, Karmiris K, Katsanos K, Kopylov U, Lakatos PL, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y, Doherty G.J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178.PMID: 34635919 No abstract available.
50. Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032). Isnard S, Fombuena B, Ouyang J, Royston L, Lin J, Bu S, Sheehan N, Lakatos PL, Bessissow T, Chomont N, Klein M, Lebouché B, Costiniuk CT, Routy B, Marette A, Routy JP; Camu Camu Study Group.BMJ Open. 2022 Jan 17;12(1):e053081. doi: 10.1136/bmjopen-2021-053081.PMID: 35039291 Free PMC article.Clinical Trial.
51. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group.Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17.PMID: 34798037 Clinical Trial.